Drug Development

Agreement Entered For Manufacturing Monoclonal Antibodies On Human Cell Line

Published in Gene Therapy Weekly, February 21st, 2002

Dutch antibody and vaccine company Crucell (CRXL) and Belgian biotechnology company Innogenetics (INNX) have entered into a nonexclusive license agreement for the manufacturing of monoclonal antibody products on Crucell's human cell line PER.C6.

Under the terms of the agreement, Innogenetics will use the PER.C6 platform to develop monoclonal antibodies in the context of its therapeutic programs, and will be able to manufacture and market the emerging therapeutic products.

Crucell's CEO Dinko Valerio welcomes Innogenetics as its launching customer for antibody production. "We are delighted with Innogenetics' choice for our technology in the context...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2002-02-21)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry